{"name":"Myung-Ju Ahn","slug":"myung-ju-ahn","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBKbVR5QUhBS0djSnd4bGk1V3hxZG5wSHhBVEV2TEJiWldTQm5nVHh1dVNKV2l2OEI3UjFYWjcwN18xYmV3bExTYWtGcnJjM0U0bHQ5WDVJRDBUYnhUemk1YWFDWmtFUlM2LU9qYjZB0gFyQVVfeXFMTkF4VTZIenhLZGNNck9UMHUwdEVUMWZodkR3MExiYms1TG1HSWdBdzRrUlJHM0dyRnN3RW5Lenp5cjdpbGJLRFZNR0x2bFU2S1E0c250QXY3cUJfYkc4S3dtTlUwV0luWDNidXViNzQ3cjV3?oc=5","date":"2026-03-13","type":"pipeline","source":"koreabiomed.com","summary":"Hanyang University Medical Center scouts world-renowned cancer expert, Prof. Ahn Myung-ju - koreabiomed.com","headline":"Hanyang University Medical Center scouts world-renowned cancer expert, Prof. Ahn Myung-ju","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE05MVlJZVVsRUdiZENoRjBPN2dNVlZ0R0x2VzlXVU9oYnNtc01rMk1KVXpZZGNHbDFTNnlXTXBKR0NGTHZnNFEyTWNjQzVNVERLMGo1X05jQktnSHFPUEFmS3J0OWVxcTJpazFfVWdn0gFyQVVfeXFMTklaUkVkQkt0UEJMVmw0MkJIeGxuSjBvbWtGVndCdnRjNXQ3Mm1KYmdaN1I3dWdlN0lWN0NCd0lTQ0dmRHZrTDBaZTVpcEszYjdxdF9TUm1oNGM1aUdpdHdoZnpKTFVmc2t4WHMwVHdPOWF3?oc=5","date":"2025-12-24","type":"pipeline","source":"koreabiomed.com","summary":"Voronoi’s 4th-gen EGFR candidate VRN11 shows distinct signal beyond Tagrisso - koreabiomed.com","headline":"Voronoi’s 4th-gen EGFR candidate VRN11 shows distinct signal beyond Tagrisso","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOUUM5ZTAzN01Pc3pXZ242a0kxcXQ1TlBmX3h2SlJvcGFWQUhqN1dpS2tfQU5QMFlYM09DZUctQXdtU0VUMDNCWkJpSnRabU96UFEzQUw1Y2hacmVkVHZVZzlJX3BSRlo3a3FLRkJlejRLMTZESWJkV0Q5bnZZa0FaaXNZRTJuaEJheDdXa3VWM0lJVkN1bHBKWk16M2UzLUNiVndZSUFEbVJjcXlMQUhyamZqZC1Sa0VnSy1qQ3BMSlF2XzZ0UVJxRTNnOFEzZm9lN3VrQzQyWndCVmJnT3BNMA?oc=5","date":"2025-11-25","type":"pipeline","source":"ascopost.com","summary":"Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC - ascopost.com","headline":"Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQT2hMMk9EYk5Md0oyYzk0elhfR2dwN0V6N2x3dTQ3NEQwcXNmdE9uZlBSMHloT2lXQ01qb0thRGZUUWoxYS1YUzBiRDBPR19la3BrdmVNMXI4UHFkQWZmWnlvenk3ZDdXZUxnUGVRMTVjQ3k0NHkxMDd0VjR4UE5NQTJhVExNOHJOR1BZRjg1aw?oc=5","date":"2025-10-20","type":"pipeline","source":"pharmaphorum","summary":"ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer - pharmaphorum","headline":"ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9ZTElnaXgzcmswNTZBdWhRWm1yb2lOWWN6SDhZSHpYbDJZVUFtNVY3WlZ5WDRFZ2NxMU1VNGRhQnY1RUwzZGRpUDF1QXVIUGVaOV9uU2FfeHpra1NrMHRvYVBGSWFDTFdMYmxmWG5B0gFyQVVfeXFMTW1NYmZNTmFLdUJCOUxsd0RqT3pMNnBXV2t3eUJPRzUyQXdOQ1J1OFdVSFg0QzZCRlJFR1haSHZSdFNBY2NWbEx1OHp2NHZEVUNER2tpbGJZb3B1S0hKdEtaYm16eXU3Um1BWjYwNXM3Z0d3?oc=5","date":"2025-10-20","type":"pipeline","source":"koreabiomed.com","summary":"[ESMO 2025] Bivalent antibody ivonescimab shows potential as a 1st-line treatment for lung cancer - koreabiomed.com","headline":"[ESMO 2025] Bivalent antibody ivonescimab shows potential as a 1st-line treatment for lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBpbURhUFoyZXlOSEp3amlGR0hZd3gydjdwVVRPYTd3Um9RZ1RZTFVtdXZhTGtjenhfWFNyVjFWTTQ0QkRfakVwOGJMVXpDTmlfNU1j?oc=5","date":"2025-10-19","type":"pipeline","source":"FirstWord Pharma","summary":"Spotlight On: This weekend's big talking points from ESMO 2025 - FirstWord Pharma","headline":"Spotlight On: This weekend's big talking points from ESMO 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE94MDk3aUpNMzlaYUJLVnJlVERKdno0ZHVZWldHTEFZY2wwOWVYUERYZ3VhSWIwU1J5NHlGWGJmS1dvR2YzZTFBeXJ3S1BYQkswV1FBRDQ5TUxjcVpPaVdiYw?oc=5","date":"2025-04-28","type":"pipeline","source":"NEJM","summary":"Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer - NEJM","headline":"Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOR3NEdzIyQVV4NDVXQmtWRTlqRm1nU2tQcHN1TWI1YXdUUG13MWQzeVlTTDRaUHhoYnlvcHREbjBJN0lJbFZOUUo3YXROeGpwajVqMWlhbmNRdUl3T01oNkU2WmlTMEhvRXdkVlFqa0NvOUFqelZucXY4MXFUcFU5RENpanFIVGR3ZVBDWmQ2R1RRU1paaW5hdXhXMkpQbUxCaVdfUUlydG1BS256?oc=5","date":"2025-03-26","type":"trial","source":"Pharmaceutical Executive","summary":"Updated Trial Results Support Tagrisso as Standard-of-Care for EGFR-Mutated Lung Cancer - Pharmaceutical Executive","headline":"Updated Trial Results Support Tagrisso as Standard-of-Care for EGFR-Mutated Lung Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9qNi1ZM1RYR1hwQlNaWXlXck4xNWdWb01QSGRFeUJRNnJTNzNrOXoteGJSV1FYYWtFeFdpVllJdDZkd3kwQ0NqalJxcWRpbUw3aWN4U3lhNzc2LXRERDU0?oc=5","date":"2025-03-17","type":"pipeline","source":"Nature","summary":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR -mutated stage IB–IIIA non-small-cell lung cancer - Nature","headline":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR -mutated stage IB–IIIA non-small-cell lung ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPcjJHOHlqaW5ybG9RRXlQa0pXQl8ycEJhWkkxRjdJeEpFWVhqdUxtR1RQc0pBemVqalFDNzY1RzBiR2c2NTRGWFFmWGFWZWZjZUxWZFBic0FQN2Z6cmRNN21OQWh3WVJxcFFpWmozb0JtMlA2ZzJhZ3ZjcjZwQnZ5akxfNWgzZWhCVVRVdHhwX0NUVXZvc1ppWmpiSThwaGpSd2tBR1piM0oyeHVPWGM3LUNJY2ZIUQ?oc=5","date":"2024-08-14","type":"regulatory","source":"Fierce Pharma","summary":"To approve Amgen's lung cancer med Imdelltra, FDA saw past 'large number' of missing adverse events - Fierce Pharma","headline":"To approve Amgen's lung cancer med Imdelltra, FDA saw past 'large number' of missing adverse events","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQX0RVbzJSeHZUa1pTWGhnYXFlVGZFTWxBUF9UdVo4TGlKdXRTb0VpaUNvVW05dnRCajhtNUJNakY2RHNsYTM3U2JFQl9rUHdsUVZzRXNYYzVhbV9GUWl2N2o2NS1rV2FtUDRWMjFsNFZPcWZKXzd5TUczS2xSMzRZY0lYQWdWVUMwOG05Tnk5Rng5SlRGbFBHSkFqMkJMajZDZWo2RU02VmYtSlRFM29CZG9EMjZ3R0ZwVGx0UnhSTmdtaWpKNHFORHJjN19fUzA5ZzRBSERrT2wwN2Q0VEhyMzhOd0t0aXpwZ1JVbGFKMUdFWXpSZUMwR3JIbmt6aGQ4UWpaVnVIRGIwdEx2WUxzVnJmRGU0WVpVTk9HQVVLSHUySGZ5?oc=5","date":"2022-02-24","type":"pipeline","source":"European Medical Journal","summary":"Evolving the Role for Immunotherapy in Lung Cancer: Extensive-Stage Small Cell Lung Cancer and Unresectable Stage III Non-small Cell Lung Cancer - European Medical Journal","headline":"Evolving the Role for Immunotherapy in Lung Cancer: Extensive-Stage Small Cell Lung Cancer and Unresectable Stage III No","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBBaHhGQ0FuQ0VMNGw4aWh5RTdfLXdaUHp3YlJGU2lzMXpoV1ZMdGZvanpwd0MzNURhd2hIUWotcUl2MlhHYmdpZllHYlVqS0xxV2ktSFEtQXNnclZNd2dnMVVHUENxNTlLMkZEUE9ucjhPREpOemJ5R3YzNA?oc=5","date":"2021-10-27","type":"pipeline","source":"acsjournals.onlinelibrary.wiley.com","summary":"Long-term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation wit","headline":"Long-term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immun","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}